Brief: Resverlogix's Betonmace Phase 3 Trial Reaches Its Targeted 250 Major Adverse Cardiac Events
18/04/2019 13:27
April 18 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX'S BETONMACE PHASE 3 TRIAL SUCCESSFULLY REACHES
ITS
TARGETED 250 MACE EVENTS
* RESVERLOGIX CORP - BETONMACE EVENT-BASED, PHASE 3
REGISTRATION
TRIAL HAS SUCCESSFULLY REACHED 250 PROJECTED MAJOR ADVERSE
CARDIAC EVENTS
* RESVERLOGIX CORP - SUCCESSFUL DATA FROM TRIAL WOULD ENABLE
RESVERLOGIX TO PROCEED TOWARDS REGULATORY APPROVAL
Source text for Eikon: ID:nGNX1WjxFh
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment